Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of 225Ac-PSMA-R2 in male adult participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors in post-177Lu and pre-177Lu settings.


Clinical Trial Description

This is an open label, phase I/II, multi-center study which contains two treatment groups (Group 1 and Group 2). Each group has a dose escalation part, once the Maximum Tolerated Dose/Recommended Dose for Expansion (MTD/RDE) is determined in each of the dose escalation parts, the study will continue with an expansion part in the respective group. The dose escalation parts will establish the MTD/RDE of the 225Ac-PSMA-R2 guided by the well-established Bayesian Logistic Regression Model (BLRM) method. The adaptive BLRM will be guided by the Escalation with Overdose Control (EWOC) principle to control the risk of DLT in future participants on study. Dose escalation decisions will be performed by the Investigators and Novartis during dose escalation meetings (DEMs) based on safety and tolerability information (BLRM summaries of DLT risk) along with PK and preliminary efficacy information. The dose expansion parts will assess the anti-tumor activity (Overall Response Rate (ORR) by Prostate Cancer Working Group 3 (PCWG3) modified RECIST 1.1 and Prostate Specific Antigen 50 (PSA50) response rate) as well as further assess the safety, tolerability, and PK of 225Ac-PSMA-R2. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05983198
Study type Interventional
Source Novartis
Contact Novartis Pharmaceuticals
Phone 1-888-669-6682
Email novartis.email@novartis.com
Status Recruiting
Phase Phase 1/Phase 2
Start date November 7, 2023
Completion date August 28, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT01977651 - A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Phase 4
Recruiting NCT04015622 - PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA Phase 2
Recruiting NCT06344715 - Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. Phase 1
Not yet recruiting NCT06134232 - Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T Phase 3
Recruiting NCT06126731 - Combination Study of Antibiotics With Enzalutamide (PROMIZE) Phase 1/Phase 2
Recruiting NCT05806814 - Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT05658003 - A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer Phase 2
Active, not recruiting NCT05670106 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC Phase 2
Recruiting NCT04691804 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 3
Completed NCT03896984 - Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Recruiting NCT06334432 - Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03074032 - Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer Phase 1
Recruiting NCT05032040 - A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Phase 2
Completed NCT03071328 - INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers Early Phase 1
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Completed NCT03030885 - Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03712930 - Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Phase 2
Recruiting NCT06241846 - A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC Phase 2
Recruiting NCT03903835 - ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Phase 3